add items to your
binder to email or
print all at once
Items In Binder
Site Lawyers

Mark I. Greene

Partner, Corporate

Mark I. Greene serves as the Head of Cravath’s Corporate Department and as the Leader of its International Practice. His practice focuses on mergers and acquisitions, corporate governance and securities matters, including advising on cross‑border transactions, private equity deals, complex restructuring transactions, proxy fights, takeover defense, hedge fund activism and global securities offerings.

Mr. Greene has been repeatedly recognized as one of the country’s leading practitioners in the mergers and acquisitions area by, among others, Chambers USA, Chambers Global, The Legal 500 United States, The Legal 500 Latin America, IFLR1000 and PLC Which Lawyer? He was recognized by The Legal 500 in 2008 and 2009 for his work in private equity buyouts. Mr. Greene was named the 2018 “Cross‑Border Dealmaker of the Year” by The Deal. In 2016, he was named a “Dealmaker of the Year” by The American Lawyer magazine and a Trailblazer in Mergers & Acquisitions by The National Law Journal. Mr. Greene was also named by Lawdragon as one of the “500 Leading Dealmakers in America” in 2007, as one of the “500 Leading Lawyers in America” in 2007 and from 2009 through 2019, and a nationwide “Legend” in 2017. For the five‑year period from 2006 to 2010, he was recognized as the second most valuable M&A lawyer in Germany by Welt am Sonntag. He was also ranked fifth in 2006 European M&A by Legal Week magazine.

Mr. Greene counts among his diverse client base Unilever, Casa Cuervo, Novartis, Schneider Electric, The Linde Group, Biogen, Mylan, Cholula, RELX Group (formerly Reed Elsevier), Synthomer, Deutsche Börse, KION Group, FS Investments and Central Garden & Pet.

Mr. Greene has advised on matters across a broad range of industries, including healthcare, consumer products, energy, financial institutions, telecommunications, media and entertainment and blockchain and financial technology (FinTech). Notable transactions include representing:

  • Mylan N.V. in connection with its pending US$50 billion combination with Upjohn, a division of Pfizer Inc., its acquisition of global marketing rights to GA Depot through an investment in and partnership with Mapi Pharma; its US$9.9 billion acquisition of Meda Aktiebolag (publ.); its acquisition of the non-sterile, topicals-focused specialty and generics business of Renaissance Acquisition Holdings, LLC for US$950 million in cash at closing plus additional contingent payments of up to US$50 million; its successful takeover defense against Teva Pharmaceutical Industries Ltd.’s US$40 billion hostile bid; its proposal to acquire Perrigo Company plc in a transaction valued at approximately US$35 billion; its acquisition of certain female healthcare businesses from Famy Care Limited for US$750 million in cash plus additional contingent payments of up to US$50 million; its US$5.6 billion inversion acquisition of Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business; its US$550 million acquisition of Bioniche Pharma Holdings Limited; its €4.9 billion acquisition of the generic drug operations of Merck KGaA of Germany; and its acquisition of Synerx Pharma LLC;
  • Unilever in connection with numerous M&A transactions, including the US$143 billion unsolicited offer from Kraft Heinz to acquire Unilever; its acquisition of OLLY Nutrition; its acquisition of Sundial Brands LLC; its US$384 million acquisition of the TAZO brand from Starbucks Corporation; its acquisition of Seventh Generation, Inc.; its acquisition of Murad, Inc.; its acquisition of Dermalogica, Inc.; its acquisition of Talenti Gelato & Sorbetto; the sale of its Slim‑Fast brand to Kainos Capital; the US$2.15 billion sale of its North America pasta sauces business under the Ragú and Bertolli brands to Mizkan Group; the US$580 million sale of its Wish‑Bone and Western dressings brands to Pinnacle Foods Inc.; the US$700 million sale of its global Skippy business to Hormel Foods; the US$267 million sale of its North American frozen meals business to ConAgra Foods, Inc.; the US$325 million sale of its Culver Specialty Brands division, which includes the Mrs. Dash, Molly McButter, Sugar Twin, Bakers and Static Guard brands in the United States and Canada, to B&G Foods, Inc.; its US$3.7 billion acquisition of U.S.‑based Alberto‑Culver Company and the sale of its Alberto VO5 brand in the U.S. and Puerto Rico from the Alberto‑Culver portfolio and the Rave brand globally from the Unilever portfolio to private equity firm Brynwood Partners VI L.P.; and its US$411.5 million acquisition of the TIGI professional hair product business and its supporting advanced education academies from the owners of the Toni & Guy Salons;
  • Synthomer plc in connection with its pending US$824 million acquisition of OMNOVA;
  • Deutsche Börse AG in connection with its US$850 million acquisition of Axioma, which was combined with Deutsche Börse’s index businesses valued at €2.6 billion, and its partnership with General Atlantic; its proposed US$9.53 billion merger of equals with NYSE Euronext and the competing unsolicited proposal by NASDAQ OMX and Intercontinental Exchange, which was withdrawn;
  • Cholula in connection with its acquisition by L Catterton;
  • Novartis AG in connection with its US$2.1 billion acquisition of Endocyte, its US$470 million acquisition of Genoptix, Inc., and the US$5.5 billion sale of its Gerber business to Nestlé S.A.;
  • RELX Group in connection with its pending US$375 million acquisition of ID Analytics, its acquisition of Aries Systems, its acquisition of Safe Banking Systems LLC, its £580 million acquisition of ThreatMetrix Inc., and LexisNexis Legal & Professional’s joint ventures with Knowable and LEAP Legal Software and LexisNexis’s acquisition of Health Market Science;
  • Jose Cuervo in connection with its US$205 million acquisition of Pendleton Whisky brands;
  • FS Investments in connection with the transition of the management of its business development company (BDC) platform to investment advisory partnerships with EIG Global Energy Partners and KKR;
  • Biogen Inc. in connection with its US$1.25 billion settlement and license agreement with Forward Pharma A/S;
  • KION Group AG in connection with its US$2.1 billion acquisition of Dematic from funds managed by AEA Investors LP and Ontario Teachers’ Pension Plan, among others;
  • Casa Cuervo in connection with an asset swap with Diageo plc in which Casa Cuervo acquired The Old Bushmills Distillery Limited, including the Bushmills Irish Whiskey brand, and Diageo acquired full ownership and control of Don Julio Tequila plus cash in the amount of US$408 million;
  • The transaction committee of the board of directors of Norwegian Cruise Line Holdings Ltd. in connection with the US$3.025 billion acquisition of Prestige Cruises International, Inc. by Norwegian;
  • Central Garden & Pet Company in connection with a US$1.1 billion unsolicited offer from Harbinger Group Inc.;
  • Integrys Energy Group, Inc. in connection with its US$9.1 billion acquisition by Wisconsin Energy Corporation;
  • The special committee of the board of directors of CNH Global N.V. in connection with the merger of Fiat Industrial S.p.A. and CNH Global with and into CNH Industrial N.V.;
  • The Linde Group in connection with its US$4.6 billion acquisition of Lincare Holdings Inc., a U.S.‑based homecare health company;
  • Schneider Electric S.A. in connection with its US$1.5 billion acquisition of Pelco, Inc., and its US$6.1 billion acquisition of American Power Conversion Corporation;
  • The Stanley Works in connection with its US$4.5 billion acquisition of The Black & Decker Corporation to create Stanley Black & Decker, an US$8.4 billion global industrial leader, in an all‑stock transaction;
  • Mangas Gaming, as U.S. counsel, in connection with its acquisition of 60% of the online gambling software business of GigaMedia Limited, including the Everest poker and casino brands;
  • NuVox, Inc. in connection with its US$643 million acquisition by Windstream Corporation;
  • Perry Capital, LLC in connection with its equity investment in Universal American Financial Corp., the proceeds of which were used by Universal American in connection with its US$630 million acquisition of MemberHealth, Inc. Mr. Greene also represented Perry Capital, LLC, as part of a consortium led by iStar Financial Inc., in connection with the US$1.7 billion sale of TimberStar Southwest LLC to Mutual Financial Corp; and
  • Royal KPN N.V. through its wholly owned subsidiary KPN B.V. in connection with its US$93.3 million acquisition of the 44% stake in iBasis Inc. not otherwise held by KPN.

Mr. Greene is a Fellow of the American College of Governance Counsel and serves on the Board of Advisors of the Institute for Law and Economics at the University of Pennsylvania. He also serves as President of the Board of Trustees of The Allen‑Stevenson School and is a Trustee of the Randall’s Island Park Alliance, both in New York City. Additionally, Mr. Greene co‑authored Corporate Law in Germany (2nd edition), an overview of the major principles of German corporate law, and the U.S. section of The Mergers and Acquisitions Review.

Mr. Greene was born in Rockaway Beach, New York. He received a B.A. from Cornell University in 1989 and a J.D. from the University of Pennsylvania in 1993. After a clerkship with Hon. Charles Legge of the U.S. District Court for the Northern District of California, he joined Cravath in 1994 and became a partner in 2001.

Mr. Greene may be reached by phone at +1‑212‑474‑1150 or by email at

Mr. Greene is admitted only in New York.

+1 (212) 474-1150
+1 (212) 474-3700